1001409-50-2
1001409-50-2 structure
- Name: MP7
- Chemical Name: 1-[(3,4-difluorophenyl)methyl]-2-oxo-N-[(1R)-2-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)oxy]-1-phenylethyl]pyridine-3-carboxamide
- CAS Number: 1001409-50-2
- Molecular Formula: C28H22F2N4O4
- Molecular Weight: 516.495
- Catalog: Signaling Pathways PI3K/Akt/mTOR PDK-1
- Create Date: 2017-01-13 05:11:50
- Modify Date: 2024-01-11 11:13:33
-
MP7 is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.
| Name | 1-[(3,4-difluorophenyl)methyl]-2-oxo-N-[(1R)-2-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)oxy]-1-phenylethyl]pyridine-3-carboxamide |
|---|---|
| Synonyms |
3-Pyridinecarboxamide, 1-[(3,4-difluorophenyl)methyl]-N-[(1R)-2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)oxy]-1-phenylethyl]-1,2-dihydro-2-oxo-
1-(3,4-Difluorobenzyl)-2-Oxo-N-{(1r)-2-[(2-Oxo-2,3-Dihydro-1h-Benzimidazol-5-Yl)oxy]-1-Phenylethyl}-1,2-Dihydropyridine-3-Carboxamide MP7 3qc4 CS-0709 1-(3,4-Difluorobenzyl)-2-oxo-N-{(1R)-2-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)oxy]-1-phenylethyl}-1,2-dihydro-3-pyridinecarboxamide PDK1 inhibitor |
| Description | MP7 is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor. |
|---|---|
| Related Catalog | |
| Target |
PDK1[1] |
| In Vitro | Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC50 values in the micromolar range[1]. |
| Cell Assay | The human GBM cells (i.e., U87MG, U343MG, or ANGM-CSS) or the respective GSCs are seeded and incubated for the indicated times with the indicated concentrations of SA16 (1 nM to 100 μM), MP7 (2.5 nM, 25 nM, 250 nM and 2.5 μM), or Alisertib. When indicated, cells are treated with MP7 and Alisertib in combination. To verify GSC chemoresistance, U87MG or GSCs are incubated with 50 μM TMZ for 72 h. For the long-term treatment of cells, NSC or complete medium containing drugs is replaced every 3 days. Cell proliferation is determined using the MTS assay: the dehydrogenase activity in active mitochondria reduces MTS to the soluble formazan product, whose absorbance at 490 nm is measured with an automated plate reader. The mean background from each test condition is subtracted, and the data are expressed as the percentage of untreated cells (control). IC50 values are derived from the sigmoid dose-response curve. The percentage of inhibition is calculated as 100% minus the percentage of cell proliferation[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 724.4±60.0 °C at 760 mmHg |
| Molecular Formula | C28H22F2N4O4 |
| Molecular Weight | 516.495 |
| Flash Point | 391.9±32.9 °C |
| Exact Mass | 516.160889 |
| PSA | 109.24000 |
| LogP | 3.32 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.640 |
| Storage condition | 2-8℃ |